SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models. We sought to determine the safety and toxicity of mocetinostat and its ability to reverse chemoresistance when administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Edwin, Ballman, Karla, Chen, James, Dickson, Mark A., Chugh, Rashmi, George, Suzanne, Okuno, Scott, Pollock, Raphael, Patel, Rajiv M., Hoering, Antje, Patel, Shreyaskumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220374/
https://www.ncbi.nlm.nih.gov/pubmed/30473623
http://dx.doi.org/10.1155/2018/2068517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220374/
https://www.ncbi.nlm.nih.gov/pubmed/30473623
http://dx.doi.org/10.1155/2018/2068517

Ejemplares similares